Targeting a herpesvirus polymerase cofactor: PF-8 inhibitors against KSHV
- Existing drugs against the KSHV DNA polymerase help patients little, so the authors targeted its processivity cofactor PF-8, which resembles the bacterial sliding clamp.
- Analogues of a hit compound gave several inhibitors with modest antiviral activity in reactivated infected cells; biophysics and NMR showed direct PF-8 binding.
- The best compounds curbed viral DNA replication and ORF45 expression, with a tert-butyl benzenesulfonamide and an N-benzylpiperazine as key features.
💡 Points Based on the abstract
Direct PF-8 binding plus modest cell potency does not yet show that the antiviral effect runs through PF-8; a binding-site mutant or resistant-virus selection would close that loop. Protein-protein interface pockets also tend to give flat SAR, so it is worth checking whether the tert-butyl sulfonamide drives affinity or merely adds lipophilicity.